Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial

Int J Clin Oncol. 2019 Dec;24(12):1629-1631. doi: 10.1007/s10147-019-01518-7. Epub 2019 Sep 3.

Authors

Atsushi Mizokami¹, Go Kimura², Yasuhisa Fujii³, Shiro Hinotsu⁴, Kouji Izumi⁵

Affiliations

¹ Department of Urology, Kanazawa University, Kanazawa, Japan. mizokami@staff.kanazawa-u.ac.jp.
² Department of Urology, Nippon Medical School, Tokyo, Japan.
³ Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.
⁴ Department of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.
⁵ Department of Urology, Kanazawa University, Kanazawa, Japan.

PMID: 31482239
DOI: 10.1007/s10147-019-01518-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Abiraterone Acetate
Bone Density
Bone Neoplasms*
Double-Blind Method
Humans
Male
Prednisolone
Prednisone
Prostatic Neoplasms*
Prostatic Neoplasms, Castration-Resistant*
Radium

Substances

Radium-223
Prednisolone
Abiraterone Acetate
Prednisone
Radium